

Supplemental Online Content

Wong SM, Blondeaux E, Delucchi V, et al. Surgical management of early-onset breast cancer among young *BRCA1/2* carriers. *JAMA Netw Open*. 2026;9(8):e2630856. doi:10.1001/jamanetworkopen.2026.30856

eTable. Factors Associated With Bilateral Mastectomy in g*BRCA1/2* Carriers With Unilateral Breast Cancer Who Underwent Genetic Testing Before or Within 3 Months of Breast Cancer Diagnosis

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable. Factors Associated With Bilateral Mastectomy in gBRCA1/2 Carriers With Unilateral Breast Cancer Who Underwent Genetic Testing Before or Within 3 Months of Breast Cancer Diagnosis

Characteristic	Total No. (N=1826) (%)	No. undergoing bilateral mastectomy (n=827) (%)	Adjusted odds ratio of receipt of bilateral mastectomy ^b OR (95% CI)
Age at breast cancer diagnosis			
<30 years	404 (22.1)	182 (22.0)	ref
31-35 years	683 (37.4)	293 (35.4)	0.90 (0.69-1.18)
36-40 years	739 (40.1)	352 (42.6)	1.09 (0.84-1.42)
Year of diagnosis			
2000-2004	55 (3.0)	15 (1.8)	ref
2005-2008	165 (9.0)	47 (5.7)	1.06 (0.51-2.18)
2009-2012	310 (17.0)	126 (15.2)	1.46 (0.74-2.86)
2013-2016	568 (31.1)	265 (32.0)	1.90 (0.98-3.69)
2017-2020	728 (39.9)	374 (45.2)	2.32 (1.20-4.50)
Geographic region			
Southern Europe	587 (32.2)	271 (32.8)	ref
Central/South America	34 (1.9)	15 (1.8)	0.81 (0.39-1.69)
Australia/Oceania	64 (3.5)	25 (3.0)	1.13 (0.64-1.99)
Northern Europe	303 (16.6)	206 (24.9)	0.96 (0.72-1.28)
Eastern Europe	121 (6.6)	49 (5.9)	0.62 (0.41-0.95)
North America	303 (16.6)	206 (24.9)	3.13 (2.29-4.29)
Asia/Africa	414 (22.7)	111 (13.4)	0.53 (0.39-0.72)
Germline BRCA pathogenic variant			
BRCA1	1234 (67.6)	583 (70.5)	ref
BRCA2	592 (32.4)	244 (29.5)	0.68 (0.52-0.88)
Histology			
Invasive ductal carcinoma	1590 (87.1)	716 (86.6)	ref
Invasive lobular carcinoma or other histology	230 (12.6)	109 (13.2)	1.08 (0.79-1.49)
Unknown histology	6 (0.3)	2 (0.2)	0.94 (0.16-5.68)
Biologic subtype			
TNBC	957 (52.4)	433 (52.4)	ref
Luminal A-like	235 (12.9)	119 (14.4)	2.10 (1.31-3.37)
Luminal B-like	419 (23.0)	192 (23.2)	1.24 (0.94-1.63)
HER2+	108 (5.9)	50 (6.1)	1.16 (0.73-1.82)
Unknown	107 (5.9)	33 (4.0)	0.90 (0.52-1.56)
Histologic grade			
Grade I	29 (1.6)	20 (2.4)	ref
Grade II	395 (21.6)	179 (21.6)	0.42 (0.18-0.98)
Grade III	1231 (67.4)	579 (70.0)	0.53 (0.21-1.29)
Unknown	171 (9.4)	49 (5.9)	0.42 (0.16-1.12)
Tumor size^a			
T1	741 (40.6)	326 (39.4)	ref
T2	830 (45.5)	388 (46.9)	0.81 (0.63-1.03)
T3-T4	218 (11.9)	97 (11.7)	0.63 (0.43-0.91)
Unknown	37 (2.0)	16 (1.9)	0.18 (0.08-0.42)
Nodal status^a			
N0	1014 (55.5)	463 (56.0)	ref
N1	599 (32.8)	277 (33.5)	0.91 (0.72-1.14)
N2-N3	191 (10.5)	74 (9.0)	0.69 (0.48-0.98)
Unknown	22 (1.2)	13 (1.6)	3.01 (1.04-8.65)
Treatment approach			
Neoadjuvant systemic therapy	864 (47.3)	470 (56.8)	ref
Upfront surgery	955 (52.3)	354 (42.8)	0.43 (0.33-0.55)
Unknown	7 (0.4)	3 (0.4)	0.51 (0.10-2.59)

^aAssessed clinically for patients who received neoadjuvant systemic therapy and pathologically for those who received upfront surgery. ^bBold if statistically significant. *TNBC* triple negative breast cancer.